Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JNJ-75220795 Single Ascending Dose in Japanese Participants with Fatty Liver
NCT05039710Phase 1Terminated
- Sponsor
- Janssen Pharmaceutical
- Start
- Nov 2021
- Primary completion
- Feb 2023
- Modality
- Conjugated siRNA, Chemically Modified siRNA
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ARO-PNPLA3 in non-alcoholic fatty liver disease (NAFLD) (2 cohorts), sponsored by Janssen Pharmaceutical. Primary endpoints: Number of Participants with Treatment-emergent Signs and Symptoms/Adverse Events (AEs), Number of Participants With Change From Baseline in Vital Signs Abnormalities and 3 more. Started Nov 2021; status: terminated.
02
Drugs
ARO-PNPLA3
03
Conditions
non-alcoholic fatty liver disease (NAFLD)
Beyond the preview
Go deeper on NCT05039710.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05039710.